Barbara Kotai

Credit Suisse termed the market reaction to Bristol-Myers Squibb Co (NYSE: BMY)'s CM-214 data as overly pessimistic. The comment was based on the 3-percent pullback in the company's shares in after-hours trading Tuesday. However, at the time of writing, shares of Bristol-Myers Squibb were down 1....